Cabergoline for Episodic Migraine

Who May Qualify: - Age ≥18 years - Episodic migraine according to ICHD-3 criteria - 4-14 monthly migraine days (MMD) in the last 3 months prior to inclusion - Stable acute migraine medication use for at least 3 months prior to inclusion - Written willing to sign a consent form Who Should NOT Join This Trial: - \< 4 MMD or ≥ 15 MMD during the baseline period - Chronic migraine (≥15 headache days per month) - Trigeminal autonomic cephalalgias and neuralgias - Secondary headache conditions - Other common primary headache types (e.g. tension-type headache) if attacks are frequent (present on an average of \>1 day/month and \>12 days/year) - Presumed medication-overuse headache - Recent changes in preventive migraine treatment (≥3 months prior to study inclusion) - History of pulmonary, retroperitoneal, or pericardial disorders, including heart valve disease - Severe untreated hypertension - Use of drugs with dopamine antagonistic or agonistic properties - Psychiatric disorders requiring pharmacological treatment - Women of child-bearing potential (i.e. not chemically or surgically sterilized, or not postmeno-pausal) and male participants with partners of child-bearing potential, who are unwilling to use a medically accepted method of contraception, considered reliable by the investigator, from signing of willing to sign a consent form and throughout the study - Women who have a positive pregnancy test at randomization - Women who are breast-feeding - Allergy or hypersensitivity to cabergoline or similar compounds - Concurrent participation in another clinical trial that, in the judgement of the investigator, may interfere with the conduct or outcomes of the present study - Inability of the subject, in the opinion of the investigator, to understand and/or comply with study medications or procedures, or any conditions that, in the opinion of the investigator, may render the subject unable to complete the study Always talk to your doctor about whether this trial is right for you.